SanSheng Pharma / 三生制药

SanSheng Pharma / 三生制药 appears in 156.生物医药的2026：当市场不再为BD躁动，中国药企的星辰大海才刚刚展开 as one of the headline Chinese innovation-drug BD cases of 2025. The episode links the company to a large [[Pfizer|辉瑞]] transaction and says a single outbound molecule received a $1.25 billion upfront payment.

The page is source-scoped. It records SanSheng as a signal in the episode’s Platform-Level Biotech BD and Biotech BD Data Validation Phase narrative, not as an independent profile or investment judgment.

Connections

• Pfizer / 辉瑞 - MNC partner named in the source.
• Biotech BD Data Validation Phase and Platform-Level Biotech BD - transaction context.
• China Biotech Asset Repricing - broader China innovation-drug validation frame.